Meeting discusses BH’s rheumatic disease-Sade

Mariana Peikoto, President of the Rheumatism Society of Minas Gerais (Photo: Leonardo Cabral / Disclosure)

“Artificial intelligence, widely applied in today’s medicine, makes it possible to develop clinical criteria to determine the optimal drug for each case.”

Mariana Peikoto, President of the Rheumatism Society of Minas Gerais

Scientific advances in immunomodulatory treatment have completely changed the view of people with rheumatic diseases. Until then, when a person was diagnosed with rheumatism, he already knew that his life would change forever, as the lack of effective medicines “blamed” him for deprivation and the daily life of sequelae. ..

These and other topics will be discussed at BH during the XIII Minas Gerais Conference on Rheumatoid Arthritis on the 24th and 25th of this month. The aim is to present treatments that provide a normal life for patients with rheumatism, with a focus on disease control with respect to behaviors such as work, family and sports.

A journey promoted by the Minas Gerais Rheumatology Society (SMR). According to the president of the entity, Mariana Peikoto, the theme of this issue is “Rheumatology and the Future”, covering the latest pharmaceutical and research advances to treat more than 120 medical conditions that are part of this group. I am.

“Artificial intelligence, widely applied in today’s medicine, makes it possible to create clinical criteria to determine the optimal drug for each case. This innovation allows disease to be ameliorated without medication. We aim to help identify and prevent patients who are more likely to develop rheumatic disease, as well as being able to find more likely patients, “he says.

No pain

Rheumatoid arthritis causes pain by damaging the musculoskeletal system, is mostly incurable and affects structures such as joints, bones, cartilage, muscles, tendons and ligaments.

Some of them can reach the kidneys, heart, lungs, eyes, skin, and even other organs such as the intestines. According to the Ministry of Health, an increasing portion of the 12 million Brazilians with one of these conditions will be able to live a normal and painless life with a minimum risk of disability. The evolution of treatment is contributing.

Mariana explains that these diseases have a genetic predisposition, but the cause has not yet been identified. Some viruses and bacteria can cause and trigger an imbalance in the immune system. “New drugs targeting a variety of therapeutic targets, such as JAK inhibitors, interleukin blockers, and complement cascade modulators, are highly effective in treating rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, scab, vasculitis, and osteoporosis. Less treatment is possible, “he explains.

The biological element is the ball of the day

The main treatment available is immunobiological. Changes are a new biological component that is a living molecule created by genetic engineering from microorganisms, but the composition of human molecules becomes more and more intimate, reducing the impact on patients and causing long-term medical conditions. Can be treated.

This innovation has revolutionized rheumatology as a medical specialty, making it possible to “stop” illness and prevent malformations. In Brazil, there are immunobiological studies such as rheumatoid arthritis, cyst, vasculitis, spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, osteoporosis, and juvenile idiopathic arthritis.

Immunotherapy is the treatment of illness by inducing control of the immune response. Immunomodulators regulate certain aspects of the immune system to increase or decrease the behavior of certain cytokines and cells. The activity and efficiency of this system can be affected by extrinsic and intrinsic factors, leading to immunosuppression or immune stimulation.

Already, immunosuppression is the activation or diminished effectiveness of the immune system. In other words, it is a type of treatment that reduces the stimulation of the immune system and attacks healthy cells. All drugs, both immunomodulators and immunosuppressants, are available options, and the indications depend on the type of disease, symptoms, and patient profile.


The program of the day also presents new treatment guidelines that are applied internationally for the treatment of various illnesses and the world’s most promising research. The treatment protocol is reviewed regularly.

Leave a Comment

Your email address will not be published.